Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES

被引:28
|
作者
Butt, Adeel Ajwad [1 ,2 ,3 ]
Yan, Peng [1 ]
Simon, Tracey G. [4 ,5 ]
Abou-Samra, Abdul-Badi [2 ,3 ,6 ]
机构
[1] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Weill Cornell Med Coll, Doha, Qatar
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
[6] Hamad Med Corp, Dept Med, Doha, Qatar
关键词
HCV; survival; sofosbuvir/ledipasvir; PrOD; ERCHIVES; HCV; RECURRENCE; DISEASE; RISK;
D O I
10.1093/cid/cix364
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Interferon-based regimens are associated with a substantial survival benefit for persons infected with hepatitis C virus (HCV). Survival data with direct-acting antiviral agents are not available. We conducted this study to quantify the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality. Methods. In the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a well-established national cohort of HCV-infected Veterans, we identified HCV-infected persons initiated on PrOD or LDV/SOF, excluding those with human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing HCV RNA or FIB-4 scores. For each case, we identified a propensity score-matched control never initiated on treatment. Primary outcome was survival. Outcomes were assessed using frequency of events, Kaplan-Meier curves, and Cox proportional hazards regression analyses. Results. We identified 1473 persons on PrOD, 5497 on LDV/SOF, and 6970 propensity score-matched untreated persons. Treated persons were more likely to be obese and have cirrhosis, but less likely to have stage 3-5 chronic kidney disease (CKD), alcohol or drug abuse or dependence diagnosis, and anemia. The proportion of persons who died was higher in the untreated group compared with either treatment group (PrOD, 0.3%; LDV/SOF, 1.4%; untreated controls, 2.5%; P<.001). A significantly larger percentage of treated patients survived to 18 months of follow-up, compared with untreated controls (P<.001). In multivariable Cox regression analysis, treatment with either regimen (hazard ratio [HR], 0.43; 95% confidence interval [CI], .33-.57) and attainment of sustained virologic response (SVR) were associated with significantly lower mortality (HR, 0.57; 95% CI, .33-.99). Conclusions. Treatment with PrOD or LDV/SOF and SVR are associated with a significant mortality benefit, apparent within the first 18 months of treatment.
引用
收藏
页码:1006 / 1011
页数:6
相关论文
共 45 条
  • [21] Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4
    Abad, Soraya
    Vega, Almudena
    Hernandez, Eduardo
    Merida, Evangelina
    de Sequera, Patricia
    Albalate, Marta
    Macias, Nicolas
    Milla, Monica
    Lopez-Gomez, Juan M.
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 45 (03) : 267 - 272
  • [22] Randomized Trial of Interferon- and Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir in Treatment-Experienced Hepatitis C Virus-Infected Patients
    Chayama, Kazuaki
    Notsumata, Kazuo
    Kurosaki, Masayuki
    Sato, Ken
    Rodrigues, Lino, Jr.
    Setze, Carolyn
    Badri, Prajakta
    Pilot-Matias, Tami
    Vilchez, Regis A.
    Kumada, Hiromitsu
    HEPATOLOGY, 2015, 61 (05) : 1523 - 1532
  • [23] Effectiveness And Safety Of Ombitasvir, Paritaprevir/Ritonavir And Sofosfuvir/Ledipasvir In Patients With Genotype 4 Chronic Hepatitis C Virus Infection: Results From The Spanish Real World Cohort
    Crespo, Javier
    Calleja, Jose L.
    Begona, Sacristran
    Ruiz-Antoran, Belen
    Ampuero, Javier
    Garcia-Samaniego, Javier
    Gea, Francisco
    Buti, Maria
    Lens, Sabela
    Cabezas, Joaquin
    Morillas, Rosa Mara
    Salcines, Jose Ramon
    Pascasio, Juan Manuel
    Turnes, Juan
    Saez-Royuela, Federico
    Arenas, Juan
    Rincon, Diego
    Prieto, Martin
    Jorquera, Francisco
    Ruano, Juan Jose Sanchez
    Navascues, Carmen
    Molina, Esther
    Torras, Xavier
    Montoliu, Silvia
    Moreno, Jose M.
    Serra, Miguel Angel
    Andrade, Raul J.
    Fernandez-Rodriuez, Conrado M.
    Fernandez-Bermejo, Miguel
    Simon, Miguel A.
    Bonet, Lucia
    de la Vega, Juan
    Diago, Moises
    Fernandez, Jose Ramon
    Sanchez-Antolin, Gloria
    Fernandez, Inmaculada
    HEPATOLOGY, 2016, 64 : 486A - 487A
  • [24] Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy
    Poordad, Fred
    Bennett, Michael
    Sepe, Thomas E.
    Cohen, Eric
    Reindollar, Robert W.
    Everson, Gregory
    Phillips, Raymond W.
    Siddique, Asma
    Sullivan, J. Greg
    Pilot-Matias, Tami
    Abunimeh, Manal
    Cohen, Daniel E.
    Younes, Ziad
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (07) : 1307 - 1312
  • [25] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1-infected patients with compensated cirrhosis and multiple comorbidities
    Popa, R. C.
    Mihai, C.
    Trifan, A.
    Stanciu, C.
    Gheorghe, L.
    Iacob, S.
    Arama, V.
    Rogoveanu, I.
    Diculescu, M.
    Goldis, A.
    Bataga, S.
    Seicean, A.
    Sandulescu, L.
    Nastase, R.
    Molagic, V.
    Brisc, C.
    Curescu, M.
    Prelipcean, C. C.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S732 - S732
  • [26] Treatment of US Veterans with hepatitis C virus (HCV) genotype (GT) 1 infection: effectiveness of Ledipasvir/Sofosbuvir (Harvoni®) and Ombitasvir/Paritavir/Ritonavir/Dasubuvir (Viekira Pak®) regimens
    Issa, Danny
    Forte, Veda
    Tassone, Daniel
    Gilles, HoChong
    Solomon, Cynthia L.
    Owens, Stacy
    Obolewicz, Barbara
    Neuman, Douglas M.
    Fuchs, Michael
    HEPATOLOGY, 2016, 64 : 991A - 992A
  • [27] Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES
    Butt, Adeel A.
    Ren, Yanjie
    Lo Re, Vincent, III
    Taddei, Tamar H.
    Kaplan, David E.
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (01) : 64 - 72
  • [28] Exposure-Safety Response Relationship for ABT 450/Ritonavir, Ombitasvir, Dasabuvir and Ribavirin in Hepatitis C Genotype 1 Virus-Infected Subjects: Analyses of Data from Phase 2 Studies
    Lin, Chih-Wei
    Menon, Rajeev
    Liu, Wei
    Mensing, Sven
    Podsadecki, Thomas
    Shulman, Nancy
    DaSilva-Tillmann, Barbara
    Awni, Walid
    Dutta, Sandeep
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S56 - S57
  • [29] Efficacy, safety, and long-term outcomes in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: TOPAZ-I interim data from Australia
    George, J.
    Desmond, P.
    Sasadeusz, J.
    Shaw, D.
    Skoien, R.
    Stuart, K.
    Hu, B. Y.
    Joy, A.
    Matias, T. P.
    Charafeddine, M.
    Cohen, D. E.
    Keane, F. M.
    Weltman, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 69 - 70
  • [30] Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials
    Poordad, Fred
    Castro, Rui Sarmento E.
    Asatryan, Armen
    Aguilar, Humberto
    Cacoub, Patrice
    Dieterich, Douglas
    Marinho, Rui
    Carvalho, Armando
    Siddique, Asma
    Hu, Yiran
    Charafeddine, Mariem
    Bondin, Mark
    Khan, Nader
    Cohen, Daniel
    Felizarta, Franco
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E745 - E746